Longhurst, HJ;
Dempster, J;
Lorenzo, L;
Buckland, M;
Grigoriadou, S;
Symons, C;
Bethune, C;
... Garcez, T; + view all
(2018)
Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom.
Allergy, Asthma & Clinical Immunology
, 14
, Article 28. 10.1186/s13223-018-0253-x.
Preview |
Text
Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom.pdf - Accepted Version Download (1MB) | Preview |
Abstract
Background Hereditary angioedema (HAE) is a potentially life-threatening, bradykinin-mediated disease, often misdiagnosed and under-treated, with long diagnostic delays. There are limited real-world data on best-practice management of HAE in the UK. Objectives To characterize the clinical profile, management and outcomes of patients with HAE type I and II from three specialist centres in the UK using data from the Icatibant Outcome Survey (IOS; Shire, Zug, Switzerland), an international observational study monitoring safety and effectiveness of icatibant, a selective bradykinin B2 receptor antagonist. Methods We performed retrospective analyses of IOS data for patients with HAE type I and II from three centres in the UK and compared UK data with pooled IOS data from 10 countries (48 centres). Results Analyses included 73 UK and 579 non-UK patients with HAE type I or II. Median diagnostic delay was 6.2 and 5.9 years, respectively. Analysis of data collected from February 2008 to July 2016 included 286 icatibant-treated attacks in 58 UK patients and 2553 icatibant-treated attacks in 436 non-UK patients (median of 3.0 attacks per patient in both groups). More attacks were treated by icatibant self-administration in UK patients (95.8%) than in non-UK patients (86.8%, p < 0.001). Time to icatibant treatment, time to resolution and attack duration were not significantly different in the UK versus non-UK patients. Conclusion UK patients from the specialist centres studied report similar diagnostic delay and similar icatibant treatment outcomes to their non-UK counterparts. However, improvements in the timely diagnosis of HAE are still required.
| Type: | Article |
|---|---|
| Title: | Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1186/s13223-018-0253-x |
| Publisher version: | https://doi.org/10.1186/s13223-018-0253-x |
| Language: | English |
| Additional information: | This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| Keywords: | C1-inhibitor defciency, Acquired angioedema, Hereditary angioedema, Icatibant, Icatibant Outcome Survey |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10068519 |
Archive Staff Only
 |
View Item |
